July 10, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the formation of a Clinical Advisory Board (CAB) to provide strategic counsel to the Company as it advances the development of BXCL501, a first-in-class sublingual thin film formulation of Dexmedetomedine, for the treatment of agitation. Additionally, the CAB will support the advancement of further candidates in BTI’s emerging neuroscience pipeline identified through its artificial intelligence (AI) innovation lab partnership with BioXcel Corporation.
There may be another chance to get this at a price below $10...takes patience... ...if that doesn't happen or you just can't wait start a 1/3 position. $11.50...is resistance until it isn't... LOOK for SIGNALS at SIGNAL LINES... I like $9 and 10 dollar stocks...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.